相关实验视频
Updated: Aug 2, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.2K
使用表观遗传修饰相关的预后签名分层骨肉瘤患者:对免疫疗法和化疗选择的影响
Zhichao Li1, Yong Xue1, Xianxing Huang1
1Orthopedics Ward 2, Shaowu Municipal Hospital of Fujian Province, Nanping, China.
Translational cancer research
|August 15, 2024
概括
这项研究开发了一种与6基因表观遗传修饰相关的预后签名 (EMRPS),用于骨肉瘤 (OS). 该EMRPS准确预测患者的生存率,并可以指导免疫疗法和化疗决策.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 生物信息学是一种生物信息学.
背景情况:
- 骨髓瘤 (OS) 存在治疗挑战,缺乏可靠的预后标志物.
- 表观遗传变化对于OS的进展至关重要.
- 这项研究的重点是使用表观遗传修饰基因 (EMG) 开发预后签名.
研究的目的:
- 使用表观遗传修饰基因 (EMG) 开发和验证骨髓瘤 (OS) 的准确预后签名.
- 探索预后签名的潜在机制.
- 预测签名对药物敏感性的影响.
主要方法:
- 使用GEO加入的TARGET-OS队列和外部验证的分析 GSE21257.
- 使用LASSO和多变Cox回归开发一个6基因预后特征 (EMRPS).
- 通过转录和免疫透分析构建预后诺莫图和探索机制.
主要成果:
- 一个6基因的EMRPS (DDX24,DNAJC1,HDAC4,SIRT7,SP140,UHRF2) 被开发出来,显示了高的预测准确度的OS生存 (AUC>0.85训练,~0.7测试).
- 预后名录集成EMRPS与临床特征进行增强的预测.
- 低风险患者表现出增加的免疫透和对西斯的敏感性.
结论:
- 建立了一个高效的EMRPS和nomogram作为OS的新预后标志物.
- 这些工具可以帮助选择免疫治疗和化疗的候选人.
- 这些发现为改进OS治疗策略提供了潜力.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...